Contact this trialFirst, we need to learn more about you.
Antisense Oligonucleotide
Daplusiran/Tomligisiran + Bepirovirsen for Chronic Hepatitis B
Recruiting0 awardsPhase 2
San Francisco, California
This trial aims to test the effectiveness and safety of two different doses of a drug combination (DAP/TOM) followed by another drug (bepirovirsen) in people with chronic hepatitis B
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service